- GlobeNewswire•3 hours agoChembio Awarded Up to $13.2 Million U.S. Government Contract to Develop and Commercialize Point-of-Care Tests for Zika Virus
MEDFORD, N.Y., Aug. 25, 2016-- Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that it has been awarded a contract for up to $13.2 million ...
- GlobeNewswire•7 days ago
MEDFORD, N.Y., Aug. 18, 2016-- Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution ...
- Zacks Small Cap Research•9 days ago
In late July Chembio preannounced expected Q2 revenue of $3.2M - $3.3M. Lower U.S. lateral flow sales and DPP sales to FIOCRUZ were cited as the reasons for the implied ~50% contraction from both the prior year period as well as from Q1 of this was year. Following the preannouncement we downwardly revised our $5.0M estimate to $3.3M, including $2.6M in product sales (from $4.2M) and $677k from license, R&D contracts and grants income (from $810k). Last week Chembio reported financial results for the second quarter ending June 30th. While grant income was well ahead of our number ($1.2M A vs. $677k E) due to greater and earlier than anticipated recognition of a bulk of the Paul G. Allen fever panel grant, product sales came in about 21% shy ($2.0M A vs. $2.6m E) of our revised estimate. The difference in actual and our revised product sales number is mostly concentrated in lower international lateral flow - which is not a particular concern given the great historical variability in this line item and the relationship to (hard to predict) international aid tenders.
Chembio Diagnostics, Inc. (CEMI)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||6.95 x 100|
|Ask||6.99 x 700|
|Day's Range||6.13 - 7.47|
|52wk Range||3.51 - 9.40|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-6.85|
|Avg Vol (3m)||76,975|
|Dividend & Yield||N/A (N/A)|